UBASH3B

Across TCGA pan-cancer cohorts, UBASH3B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated UBASH3B data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher UBASH3B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBASH3B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, COAD, and STAD are the cancer types where UBASH3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.112	0.627	<.001	30	view →
COAD	OS	Median	All	0.082	0.871	<.001	27	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
UCEC	DFS	Median	All	0.971	0.611	.006	12	view →
SKCM	OS	Median	III,IV	0.218	0.849	<.001	11	view →
PRAD	DFS	Median	All	0.670	0.935	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

UBASH3B–BLCA (DFS)

Open the BLCA breakdown →